<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03208023</url>
  </required_header>
  <id_info>
    <org_study_id>170601</org_study_id>
    <nct_id>NCT03208023</nct_id>
  </id_info>
  <brief_title>RESIPI for Reducing Perioperative Major Adverse Cardiac Events</brief_title>
  <acronym>RESIPI</acronym>
  <official_title>RESIPI for Reducing Perioperative Major Adverse Cardiac Events: A Phase II Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cheetah Medical Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the effect of a novel hemodynamic management and monitoring
      strategy for reducing cardiac bio marker elevations and major adverse cardiac events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Modest elevations in cardiac biomarkers in the immediate postoperative period are associated
      with significantly increased risk of morbidity and mortality. The RESIPI model of hemodynamic
      monitoring and management in the perioperative period takes into account the dynamic
      interplay of vascular resistance, inotropy, and fluid management. This study aims to evaluate
      the effect of a novel hemodynamic management and monitoring strategy for reducing cardiac bio
      marker elevations and major adverse cardiac events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2017</start_date>
  <completion_date type="Anticipated">November 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>B-typer Natriuretic Peptide (BNP)</measure>
    <time_frame>Post Op day 1</time_frame>
    <description>Change in BNP (&gt;250 ng/ml)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days post op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major cardiac events</measure>
    <time_frame>30 days post op</time_frame>
    <description>Occurrence of major cardiac events (new arrhythmia, myocardial ischemia/infarction, congestive heart failure, or in-hospital cardiac arrest)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>Approximately 3-5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission rate (Emergency room or hospital)</measure>
    <time_frame>30 days post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return to operating room</measure>
    <time_frame>30 days post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total hospital cost</measure>
    <time_frame>30 days post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of significant medical events</measure>
    <time_frame>30 days post operative</time_frame>
    <description>Occurrence of significant medical events (stroke, delirium, pneumonia, new oxygen requirement, need for re-intubation, acute kidney injury (KDIGO criteria), hyperglycemia (glucose &gt;180)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days at home in first 30 days</measure>
    <time_frame>30 days post operative</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Inotropy</condition>
  <condition>Fluid Management</condition>
  <condition>Cardiac Event</condition>
  <condition>Perioperative Cardiac Risk</condition>
  <condition>Vascular Resistance</condition>
  <condition>Hemodynamic Monitoring</condition>
  <condition>Hemodynamic Management</condition>
  <condition>Fluid Responsiveness</condition>
  <arm_group>
    <arm_group_label>Standard intraoperative care- no interventions</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard intraoperative hemodynamic monitoring and treatment at Vanderbilt University Medical Center - No study interventions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RESIPI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraoperative implementation of RESIPI management strategy, a structured hemodynamic monitoring and treatment plan: RESIPI includes normalization of vascular resistance, correction of fluid responsiveness, and inotropy, and hemodynamic monitoring with the Starling SV (Cheetah Medical).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RESIPI Management Strategy</intervention_name>
    <description>a structured hemodynamic monitoring and treatment plan: RESIPI includes normalization of vascular resistance, correction of fluid responsiveness, and inotropy, and hemodynamic monitoring with the Starling SV (Cheetah Medical, Inc).</description>
    <arm_group_label>RESIPI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Standard intraoperative care- no interventions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Revised Cardiac Risk Index greater than or equal to 1, history of diastolic
             dysfunction, or age greater than 55 years.

          -  Surgery type: Major Abdominal Oncologic Surgery

          -  Planned surgery length greater than or equal to 90 minutes with planned in-patient
             stay of at least 2 days

        Exclusion Criteria:

          -  Patients who are unstable by current American Heart Association/American College of
             Cardiology Clinical Practice Guidelines

          -  Patients with Chronic Kidney Disease Stage IV or V

          -  Urgent/emergent surgical interventions (e.g. Level 1 or 2 by VUMC VOR definitions)

          -  No signs of ischemia, congestive heart failure, or volume overload: Creatinine
             Clearance greater than 30
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew D McEvoy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew D McEvoy, M.D.</last_name>
    <phone>615-936-5194</phone>
    <email>matthew.d.mcevoy@vanderbilt.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gail Mayo, RN</last_name>
    <phone>6156-936-1705</phone>
    <email>gail.mayo@vanderbilt.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew D McEvoy, M.D.</last_name>
      <phone>615-936-5194</phone>
      <email>matthew.d.mcevoy@vanderbilt.edu</email>
    </contact>
    <contact_backup>
      <last_name>Gail Mayo, RN</last_name>
      <phone>615-936-1705</phone>
      <email>gail.mayo@vanderbilt.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam B King, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tracy McGrane, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Shaw, MB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kamran Idrees, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2017</study_first_submitted>
  <study_first_submitted_qc>June 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2017</study_first_posted>
  <last_update_submitted>November 30, 2017</last_update_submitted>
  <last_update_submitted_qc>November 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Matthew McEvoy</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

